Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CALITHERA BIOSCIENCES, INC.

(CALA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Calithera Agrees to Acquire 2 Clinical-Stage Assets from Takeda Pharma

10/18/2021 | 02:39pm EST

By Stephen Nakrosis

Biopharmaceutical company Calithera Biosciences Inc. on Monday said was expanding its oncology pipeline as it agreed to acquire two clinical-stage compounds from Takeda Pharmaceutical Co. Ltd.

Calithera said the compounds, sapanisertib and mivavotinib, strengthen its pipeline of clinical-stage targeted therapies. Susan Molineaux, the company's president and chief executive, said "We believe that these clinical-stage compounds are an excellent complement to our internally-developed pipeline programs, and fit well with our current strategic focus on biomarker-driven therapeutic approaches."

She also said the company plans to start clinical trials for both compounds and generate data in the next 12 to 18 months.

At 4:18 p.m. ET, Calithera stock had risen 4.48% to $2.10.

The stock finished the day's regular-trading session with a 1.47% loss, closing at $2.01 a share.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

10-18-21 1639ET

Stocks mentioned in the article
ChangeLast1st jan.
CALITHERA BIOSCIENCES, INC. -10.25% 0.7162 Delayed Quote.-85.41%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 1.55% 3070 End-of-day quote.-18.24%
All news about CALITHERA BIOSCIENCES, INC.
11/12Calithera to Present at the 2021 Jefferies London Healthcare Conference
AQ
11/09CALITHERA : Q3 Earnings Snapshot
AQ
11/09CALITHERA BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
11/09Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlight..
PU
11/09Investor Deck
PU
11/09Calithera Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
CI
11/09Earnings Flash (CALA) CALITHERA BIOSCIENCES Posts Q3 Revenue $6.8M
MT
11/09Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlight..
AQ
11/08Calithera Biosciences Promotes Emil T. Kuriakose, MD, to Chief Medical Officer
AQ
11/08Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial
AQ
More news
Analyst Recommendations on CALITHERA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 9,79 M - -
Net income 2021 -62,4 M - -
Net cash 2021 65,0 M - -
P/E ratio 2021 -0,85x
Yield 2021 -
Capitalization 53,7 M 53,7 M -
EV / Sales 2021 -1,16x
Capi. / Sales 2022 53,7x
Nbr of Employees 93
Free-Float 99,2%
Chart CALITHERA BIOSCIENCES, INC.
Duration : Period :
Calithera Biosciences, Inc. Technical Analysis Chart | CALA | US13089P1012 | MarketScreener
Technical analysis trends CALITHERA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 0,72 $
Average target price 1,83 $
Spread / Average Target 156%
EPS Revisions
Managers and Directors
Susan M. Molineaux President, Chief Executive Officer & Director
Stephanie Wong Secretary, Chief Financial & Accounting Officer
Francesco Parlati Senior Vice President-Research
Susan B Demo Vice President-Medical Affairs
Emil T. Kuriakose Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CALITHERA BIOSCIENCES, INC.-85.41%54
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819